AMLX Amylyx Pharmaceuticals Inc

Price (delayed)

$14.1

Market cap

$1.57B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$1.34B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 11

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a ...

Highlights
Amylyx Pharmaceuticals's revenue has soared by 100% YoY
AMLX's gross profit has surged by 100% year-on-year
The equity rose by 36% year-on-year but it has declined by 11% since the previous quarter
Amylyx Pharmaceuticals's net income has increased by 31% YoY but it has decreased by 3.7% QoQ

Key stats

What are the main financial stats of AMLX

AMLX stock price

How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
6.82%
1 week
-0.84%
1 month
-14.34%
1 year
186.59%
YTD
16.72%
QTD
1.44%

Financial performance

How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$159.27M
Net income
-$150.11M
Gross margin
N/A
Net margin
N/A
Amylyx Pharmaceuticals's revenue has soared by 100% YoY
AMLX's gross profit has surged by 100% year-on-year
Amylyx Pharmaceuticals's net income has increased by 31% YoY but it has decreased by 3.7% QoQ
The company's operating income rose by 31% YoY but it fell by 3.9% QoQ

Price vs fundamentals

How does AMLX's price correlate with its fundamentals

Growth

What is Amylyx Pharmaceuticals's growth rate over time

Valuation

What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AMLX's EPS has surged by 52% year-on-year and by 3.3% since the previous quarter
AMLX's P/B is 41% above its 5-year quarterly average of 3.8 and 24% above its last 4 quarters average of 4.3
The equity rose by 36% year-on-year but it has declined by 11% since the previous quarter
Amylyx Pharmaceuticals's revenue has soared by 100% YoY

Efficiency

How efficient is Amylyx Pharmaceuticals business performance
Amylyx Pharmaceuticals's ROE has increased by 48% YoY and by 3.1% from the previous quarter
Amylyx Pharmaceuticals's ROA has increased by 42% YoY and by 2.9% from the previous quarter
The company's return on invested capital fell by 28% QoQ

Dividends

What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMLX.

Financial health

How did Amylyx Pharmaceuticals financials performed over time
The quick ratio has soared by 53% YoY and by 25% from the previous quarter
The current ratio is up by 48% year-on-year and by 25% since the previous quarter
Amylyx Pharmaceuticals's debt is 98% less than its equity
AMLX's debt to equity has soared by 100% year-on-year
The equity rose by 36% year-on-year but it has declined by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.